DarioHealth Launches $20 Million At-The-Market Equity Program

DarioHealth ( (DRIO) ) has issued an update.

On March 30, 2026, DarioHealth Corp. entered into a sales agreement with A.G.P./Alliance Global Partners to launch an at-the-market equity program allowing the company to issue and sell up to $20 million of common stock from time to time. The shares will be sold under an effective shelf registration statement, with A.G.P. acting as sales agent or principal for a 3% commission plus expenses, and the company retaining the right to suspend or terminate the program at its discretion.

Potential net proceeds may be used to fund commercial, sales and marketing activities, research and development, mergers and acquisitions, other corporate purposes, repayment of indebtedness under its credit facility with Callodine Commercial Finance, and general working capital, providing flexible capital for growth and balance-sheet management. The structure and customary indemnification and termination provisions of the agreement align DarioHealth with common capital-raising practices in the public markets, while giving stakeholders visibility into the company’s potential financing path without obligating it to issue all authorized shares.

The most recent analyst rating on (DRIO) stock is a Sell with a $7.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.

Spark’s Take on DRIO Stock

According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.

The score is held down primarily by weak financial performance (ongoing operating losses and sustained cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting this, the latest earnings call conveyed improving unit economics and a credible cost-reduction and commercialization plan, but near-term revenue ramp and funding/cash execution risk remain key constraints.

To see Spark’s full report on DRIO stock, click here.

More about DarioHealth

DarioHealth Corp. is a digital health company that develops and markets technology-enabled solutions for chronic condition management. Its primary offerings focus on commercial, sales and marketing-driven programs, supported by ongoing research and development, with a business model that can be expanded through mergers and acquisitions and related corporate initiatives.

Average Trading Volume: 14,949

Technical Sentiment Signal: Sell

Current Market Cap: $59.21M

Find detailed analytics on DRIO stock on TipRanks’ Stock Analysis page.